Blood Banks Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Product Type (Whole Blood, Red Blood Cells, Platelets, Plasma, Others), By Function (Collection, Processing, Testing, Storage, and Transportation), By Ownership (Private v/s Public), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Pharmaceutical Companies, Others), By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 22.54 Billion
CAGR (2026-2031)	3.98%
Fastest Growing Segment	Public
Largest Market	North America
Market Size (2031)	USD 28.49 Billion

Market Overview

The Global Blood Banks Market will grow from USD 22.54 Billion in 2025 to USD 28.49 Billion by 2031 at a 3.98% CAGR. The Global Blood Banks Market encompasses the specialized infrastructure and processes responsible for the collection, screening, processing, storage, and distribution of whole blood and derived components such as plasma, platelets, and red blood cells. The market's growth is fundamentally supported by the escalating prevalence of chronic hematological disorders, an aging global population requiring frequent transfusions, and the rising volume of complex surgical procedures and trauma cases. These core drivers ensure a continuous, non-discretionary demand for safe blood products, providing a stable foundation for market development distinct from temporary technological trends.

However, a significant challenge impeding market expansion is the persistent volatility of blood inventories due to fluctuating donor participation rates and supply chain constraints. This instability often results in critical shortages that threaten the continuity of patient care. According to America's Blood Centers, in 2024, approximately one-third of community blood centers across the United States were reported to be operating with a critically low supply of one day or less. Such precarious inventory levels highlight the difficulty in balancing voluntary donation inflows with the consistent therapeutic demand from healthcare providers.

Key Market Drivers

The rising prevalence of hematological disorders and chronic diseases constitutes a primary catalyst for the Global Blood Banks Market. Patients undergoing aggressive chemotherapy or managing chronic blood conditions often require frequent and substantial transfusions of platelets, plasma, and red blood cells to maintain physiological stability. This dependency creates a non-discretionary demand for blood products, necessitating rigorous collection and storage protocols to support long-term therapeutic care. According to the American Cancer Society, January 2024, in the 'Cancer Facts & Figures 2024', the United States projected a total of 2,001,140 new cancer cases for the year. Such high incidence rates compel blood banks to expand their operational capacities and inventory reserves to ensure the uninterrupted availability of vital blood components for oncological and chronic disease treatments.

Concurrently, the market is significantly driven by the increasing volume of complex surgical procedures and organ transplants, which demand immediate access to compatible blood supplies. Major surgeries, including cardiovascular interventions and orthopedic replacements, carry a high risk of hemorrhage, making the availability of diverse blood groups critical for patient survival. According to the United Network for Organ Sharing, January 2024, in the '2023 Organ Transplants' announcement, the U.S. system achieved a historic milestone with more than 46,000 transplants performed in 2023. However, meeting this escalating surgical demand is challenging amidst shifting donor behaviors. According to the American Red Cross, in 2024, the number of individuals donating blood has declined by approximately 40% over the last twenty years, pressuring blood banks to implement more efficient inventory management systems.

Download Free Sample Report

Key Market Challenges

The persistent volatility of blood inventories, driven by fluctuating donor participation rates and supply chain constraints, acts as a primary restraint on the growth of the Global Blood Banks Market. This instability disrupts the operational continuity required for market expansion, as blood centers must frequently divert strategic resources toward immediate supply management rather than infrastructure development. When collection rates fail to align with the steady therapeutic demand from healthcare providers, the resulting unpredictability compromises the ability of blood banks to fulfill long-term supply contracts, thereby deterring investment in advanced processing capabilities and logistical networks.

The impact of this inventory instability is illustrated by recent industry data. According to the American Red Cross, in 2024, the organization reported that its national blood inventory plummeted by more than 25 percent during the month of July, triggering an emergency shortage. Such acute deficits directly impede market growth by forcing medical institutions to postpone elective surgeries and ration essential blood products. Consequently, the inability to maintain reliable stock levels limits transaction volumes and undermines the market's capacity to support the escalating frequency of complex medical procedures.

Key Market Trends

The accelerated adoption of automated blood processing and screening systems is reshaping the market by enhancing operational efficiency and reducing manual errors in high-volume donor centers. Laboratories are increasingly integrating fully automated analyzers to streamline immunohematology testing and compatibility screening, which ensures rapid turnaround times for critical transfusions. This shift towards automation addresses the dual challenge of labor shortages and the need for standardized testing protocols across expanding healthcare networks. According to Grifols, October 2025, in the 'Grifols expands US diagnostic manufacturing with a new facility in San Diego' announcement, the company’s diagnostic division achieved 15% growth in North America in 2024, driven by the rising demand for its advanced blood typing solutions and reagents.

The increasing utilization of pathogen reduction technologies represents a critical advancement in safeguarding the blood supply against emerging infectious threats and bacterial contamination. These systems use photochemical processes to inactivate viruses, bacteria, and parasites in platelet and plasma components, thereby adding a robust layer of safety beyond traditional screening methods. The technology is gaining traction as blood centers prioritize risk mitigation strategies to protect vulnerable patient populations receiving frequent transfusions. According to Cerus Corporation, January 2025, in the 'Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue' report, the company recorded a 42% growth in revenue for its INTERCEPT Fibrinogen Complex over the previous year, highlighting the expanding commercial adoption of its pathogen inactivation systems.

Segmental Insights

The public segment is currently emerging as the fastest-growing category within the Global Blood Banks Market. This accelerated expansion is primarily driven by increasing government initiatives aimed at establishing a secure and self-sufficient national blood supply. Regulatory entities such as the World Health Organization actively advocate for voluntary non-remunerated blood donations, a policy that significantly strengthens the operational capacity of state-run facilities. Furthermore, rising healthcare expenditures in developing regions allow for the continuous improvement of public collection infrastructure, ensuring affordable access to essential blood products for trauma and emergency care.

Regional Insights

North America maintains a leading position in the global blood banks market primarily due to a highly developed healthcare infrastructure and rising instances of blood disorders. The dominance of this region is supported by stringent safety regulations regarding collection and screening enforced by the U.S. Food and Drug Administration. Furthermore, organizations such as the American Red Cross facilitate a strong voluntary donor network, ensuring a consistent supply of blood components. Comprehensive reimbursement policies and continuous government support for safe transfusion practices also contribute significantly to the sustained market leadership of North America.

Recent Developments

• In December 2025, Cerus Corporation entered into a group purchasing agreement with the Blood Centers of America, a large network of independent community blood centers. This commercial collaboration was established to facilitate broader access to the company's pathogen reduction system and other related products among the network's member organizations. The agreement highlighted the industry's continued focus on safeguarding the blood supply against emerging pathogens and ensuring the availability of safe blood components. Through this partnership, the company aimed to strengthen its market presence and support blood centers in adopting technologies that enhance transfusion safety and operational readiness.
• In September 2024, Terumo Blood and Cell Technologies announced a strategic collaboration with Nova Biomedical to integrate automated cell culture sensing capabilities into its cell expansion system. This partnership involved incorporating a specialized automated cell culture analyzer, which enabled real-time monitoring and control of critical parameters during the cell manufacturing process. The integration was designed to support blood and cell centers in scaling up their operations from research to commercial manufacturing. By automating the sampling and analysis steps, the collaboration aimed to streamline workflows and improve the consistency and quality of cell-based therapies produced by organizations in the market.
• In May 2024, CSL Plasma obtained clearance from the U.S. Food and Drug Administration for a new individualized nomogram to be used with its proprietary plasma donation system. This regulatory milestone allowed for a more tailored approach to plasma collection, optimizing the volume of plasma collected from each donor based on their specific body composition. The approval was part of the company's broader strategy to deploy advanced technology across its network of donation centers, aiming to enhance the donor experience and improve operational efficiency in the collection of human plasma for essential therapies within the blood banking sector.
• In March 2024, Roche received approval from the U.S. Food and Drug Administration for a molecular test designed to screen blood donors for malaria. This approval marked a significant advancement in ensuring the safety of the global blood supply, as it was the first FDA-approved molecular test for this specific application. The test was developed to operate on the company's automated systems, allowing blood centers to efficiently identify and remove infected blood units. This development addressed the challenge of screening donors who had traveled to malaria-endemic regions, thereby potentially increasing the pool of eligible blood donors while maintaining high safety standards.

Key Market Players

• American Association of Blood Banks
• America's Blood Centres
• Australian Red Cross Society
• Blood Bank of Alaska
• Canadian Blood Services
• Japanese Red Cross Society
• New York Blood Centre
• Sanquin Blood Supply Foundation
• The American Red Cross

By Function	By Ownership	By End User	By Region
Collection Processing Testing Storage and Transportation	Private v/s Public	Hospitals & Clinics Ambulatory Surgery Centers Pharmaceutical Companies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Blood Banks Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Blood Banks Market, By Function:

• Collection
• Processing
• Testing
• Storage
• and Transportation

• Blood Banks Market, By Ownership:

• Private v/s Public

• Blood Banks Market, By End User:

• Hospitals & Clinics
• Ambulatory Surgery Centers
• Pharmaceutical Companies
• Others

• Blood Banks Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE